Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: A pilot study Journal Article
| Authors: | Wild, D.; Fani, M.; Fischer, R.; Pozzo, L. D.; Kaul, F.; Krebs, S.; Rivier, J. E. F.; Reubi, J. C.; Maecke, H. R.; Weber, W. A. |
| Article Title: | Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: A pilot study |
| Abstract: | Preclinical and clinical studies have indicated that somatostatin receptor (sst)-expressing tumors demonstrate higher uptake of radiolabeled sst antagonists than of sst agonists. In 4 consecutive patients with advanced neuroendocrine tumors, we evaluated whether treatment with 177Lu- labeled sst antagonists is feasible. Methods: After injection of approximately 1 GBq of 177Lu-DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr- NH2] (177Lu-DOTA-JR11) and 177Lu-DOTATATE, 3-dimensional voxel dosimetry analysis based on SPECT/CT was performed. A higher tumor-to-organ dose ratio for 177Lu-DOTAJR11 than for 177Lu-DOTATATE was the prerequisite for treatment with 177Lu-DOTA-JR11. Results: Reversible minor adverse effects of 177Lu-DOTA-JR11 were observed. 177Lu-DOTA-JR11 showed a 1.7-10.6 times higher tumor dose than 177Lu-DOTATATE. At the same time, the tumor-to-kidney and tumor-to-bone marrow dose ratio was 1.1-7.2 times higher. All 4 patients were treated with 177Lu-DOTA-JR11, resulting in partial remission in 2 patients, stable disease in 1 patient, and mixed response in the other patient. Conclusion: Treatment of neuroendocrine tumors with radiolabeled sst antagonists is clinically feasible and may have a significant impact on peptide receptor radionuclide therapy. COPYRIGHT © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc. |
| Keywords: | cancer chemotherapy; aged; unclassified drug; clinical trial; case report; drug efficacy; drug safety; multiple cycle treatment; thrombocytopenia; neuroendocrine tumor; lung tumor; cancer regression; feasibility study; diagnostic agent; drug uptake; isotope labeling; pilot study; dosimetry; radiopharmaceutical agent; drug half life; bladder carcinoma; single photon emission computer tomography; drug excretion; neuroendocrine tumors; antagonists; comparative effectiveness; ileum tumor; human; male; female; priority journal; article; somatostatin receptor targeting; lutetium tetraxetan jr11 lu 177; lutetium tetraxetan octreotide[3 tyrosine] lu 177 |
| Journal Title: | Journal of Nuclear Medicine |
| Volume: | 55 |
| Issue: | 8 |
| ISSN: | 0161-5505 |
| Publisher: | Society of Nuclear Medicine |
| Date Published: | 2014-06-24 |
| Start Page: | 1248 |
| End Page: | 1252 |
| Language: | English |
| DOI: | 10.2967/jnumed.114.138834 |
| PROVIDER: | scopus |
| PUBMED: | 24963127 |
| DOI/URL: | |
| Notes: | Export Date: 2 September 2014 -- CODEN: JNMEA -- Source: Scopus |
